MARKET

PASG

PASG

Passage Bio, Inc.
NASDAQ
8.22
-0.55
-6.22%
Pre Market: 10.50 +2.29 +27.82% 06:49 04/08 EDT
OPEN
8.66
PREV CLOSE
8.76
HIGH
9.26
LOW
7.55
VOLUME
1
TURNOVER
0
52 WEEK HIGH
20.00
52 WEEK LOW
5.12
MARKET CAP
26.35M
P/E (TTM)
-0.5726
1D
5D
1M
3M
1Y
5Y
1D
Passage Bio announces annual shareholder meeting via virtual webcast
Reuters · 1d ago
Weekly Report: what happened at PASG last week (0330-0403)?
Weekly Report · 2d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 04/01 12:05
Passage Bio Initiated at Outperform by Oppenheimer
Dow Jones · 03/31 14:07
Passage Bio Price Target Announced at $30.00/Share by Oppenheimer
Dow Jones · 03/31 14:07
Oppenheimer Initiates Coverage On Passage Bio with Outperform Rating, Announces Price Target of $30
Benzinga · 03/31 13:58
PASSAGE BIO INC <PASG.O>: OPPENHEIMER INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $30
Reuters · 03/31 12:29
Analysts Have Conflicting Sentiments on These Healthcare Companies: Passage Bio (PASG), Phreesia (PHR) and Esperion (ESPR)
TipRanks · 03/31 08:50
More
About PASG
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It also has a preclinical research program that explores multiple potential treatment targets for Huntington's disease.

Webull offers Passage Bio Inc stock information, including NASDAQ: PASG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PASG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PASG stock methods without spending real money on the virtual paper trading platform.